Rapid Workforce Growth Array BioPharma is expanding significantly, with plans to hire nearly 100 additional employees following a 22-acre expansion. This growth indicates increased operational capacity and potential demand for related services, supplies, and support solutions tailored to a scaling biotech environment.
Strategic Collaborations The company's recent collaborations, such as developing ARRY-380 with Oncothyreon and partnerships with AstraZeneca, Roche, and Cascadian Therapeutics, highlight ongoing drug development initiatives. Opportunities exist for supporting clinical research, laboratory equipment, and partnership facilitation services.
Focus on Oncology Innovation Array BioPharma's specialization in targeted small molecule therapies for cancer presents opportunities to connect with healthcare providers, hospitals, and pharmaceutical companies involved in oncological treatment, diagnostics, and personalized medicine solutions.
Technological Investment The company's adoption of advanced tech stacks like Google Conversion Tracking, Concrete CMS, and New Relic suggests a focus on digital marketing and operational efficiency, indicating potential needs for marketing, analytics, and IT infrastructure enhancements.
Industry Acquisition Backing Having been acquired by Pfizer for over 11 billion dollars, Array BioPharma demonstrates strong financial backing and market valuation. This stability provides a platform for upselling high-value solutions in research, clinical trials, and commercialization services.